On October 28, gtja research reports pointed out that jiangsu hengrui pharmaceuticals (600276.SH) Q3 revenue, net income attributable to shareholders, non-net income attributable to shareholders were 6.589 billion, 1.188 billion, 1.126 billion yuan, with a year-on-year increase of +12.72%, +1.91%, +0.84%, showing steady performance growth. The period of innovation and upgrade has entered the harvest period, which is expected to accelerate performance. Products are gradually going global, and the international layout is accelerating realization. Increased investment in research and development, good control of sales & management expenses ratio. Maintain a 'shareholding' rating.
研报掘金丨国泰君安：恒瑞医药业绩稳健增长，维持“增持”评级
Research reports | gtja: jiangsu hengrui pharmaceuticals performance steady growth, maintain "shareholding" rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated